Table 3.

Second-line chemotherapy trials in patients with advanced gastric cancer

Ref.	Regimen	No. of patients	Response rate	Median PFS/TTP and OS (mo)
Kang et al[82]	Docetaxel or irinotecan + BSC vs BSC	202	-	TTP, NA; OS, 5.3 vs 3.8
Thuss-Patience et al[83]	Irinotecan vs BSC	40	44% vs 5%	PFS, 2.6 vs NA; OS, 4.0 vs 2.4
Ford et al[84]	Docetaxel + BSC vs BSC	168	7% vs NA	PFS, 5.6 vs 5.0; OS, 5.2 vs 3.6
Shimada et al[85]	Irinotecan + cisplatin vs irinotecan	130	21.9% vs 16.4%	PFS, 4.17 vs 3.03; OS, NA

BSC: Best supportive care; NA: Not applicable; PFS: Progression-free survival; OS: Overall survival; TTP: Time-to progression.